Can straight men with castration‑resistant metastatic prostate cancer receiving androgen‑deprivation therapy and chemotherapy change their sexual orientation to become receptive (bottom) partners?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sexual Orientation Does Not Change with Prostate Cancer Treatment

No, straight men with castration-resistant metastatic prostate cancer (CRPC) do not change their sexual orientation to become gay or receptive partners as a result of androgen deprivation therapy (ADT) or chemotherapy. Sexual orientation is a fundamental aspect of identity that is not altered by hormonal manipulation or cancer treatment.

What Actually Happens: Sexual Function Changes, Not Orientation

Effects of ADT on Sexual Function

ADT profoundly impacts sexual function through multiple mechanisms 1, 2:

  • Loss of libido (sexual desire)
  • Erectile dysfunction
  • Genital atrophy and shrinkage
  • Loss of ejaculate
  • Feminizing body changes (loss of muscle mass, breast development, fat redistribution)
  • Hot flashes and fatigue

These changes typically result in cessation of all sexual activity for most men 2. The treatment creates castrate levels of testosterone, fundamentally altering sexual capacity rather than sexual orientation.

Sexual Orientation Remains Stable

Research examining both heterosexual and homosexual men with prostate cancer demonstrates that sexual orientation itself does not change 3. What does change is:

  • Sexual function capacity (ability to perform sexually)
  • Sexual interest/motivation (desire for sexual activity)
  • Sexual behavior patterns (how men express sexuality within their existing orientation)

Gay and Bisexual Men: Role-in-Sex Changes (Not Orientation Changes)

For gay and bisexual men who were already sexually active with male partners before treatment, research shows some do experience changes in their role-in-sex preferences 4:

  • Shifts predominantly occur from "top" (insertive) to "bottom" (receptive) roles
  • This represents adaptation to erectile dysfunction, not a change in sexual orientation
  • Men who maintain a top role have significantly better sexual and mental health outcomes
  • These changes reflect loss of erectile function making insertive intercourse difficult or impossible

Critical distinction: These are gay/bisexual men adapting their sexual practices within their pre-existing orientation due to treatment side effects—not heterosexual men becoming gay.

Adaptation Strategies That Actually Occur

Research on sexual adaptation after prostate cancer treatment identifies several patterns 5, 2:

Couples-Focused Adaptations

  • Relationship renegotiation: Redefining intimacy beyond penetrative sex
  • Sexual renegotiation: Finding new ways to express sexuality together
  • Emphasis on emotional connection over physical performance

Individual-Focused Adaptations

  • Acceptance/resignation: Abandoning partnered sexual activity
  • Masturbation focus: Shifting to solo sexual expression
  • Emphasis on maintaining erectile function for self-image

Common Outcome

Most men (and couples) who do not actively adapt experience complete cessation of sexual activity 1, 2. The median sexual satisfaction for men on ADT is 0 out of 10 1.

Clinical Implications

What Providers Should Address

Sexual function counseling should focus on 6, 7:

  1. Realistic expectations: Most men will experience severe sexual dysfunction
  2. Relationship impact: Partners are significantly affected; include them in discussions
  3. Adaptation options:
    • Erectile aids (PDE-5 inhibitors, vacuum devices, injections)
    • Redefining intimacy and sexual expression
    • Couples counseling or sex therapy
  4. Mental health: Depression and anxiety are common with sexual changes

Special Considerations for Sexual Minority Patients

For gay and bisexual men 4:

  • Ask specifically about role-in-sex to provide appropriate counseling
  • Loss of ejaculate is particularly distressing (more than for heterosexual men)
  • Higher risk of depression and anxiety with sexual changes
  • Need culturally competent care addressing their specific concerns

The Bottom Line

Sexual orientation is not influenced by prostate cancer treatment. What changes is sexual function and capacity. Heterosexual men remain heterosexual but typically lose the ability to engage in sexual activity as they did before treatment. Gay and bisexual men remain gay/bisexual but may adapt their sexual practices within that orientation due to erectile dysfunction and other treatment effects.

The question reflects a fundamental misunderstanding of both sexual orientation (which is stable) and treatment effects (which impact function, not identity). Focus clinical discussions on managing sexual dysfunction, supporting relationship adaptation, and addressing quality of life—not on orientation change, which does not occur 8, 6, 7.

Related Questions

Can a man with metastatic prostate cancer receiving androgen‑deprivation therapy and chemotherapy have sexual activity without a firm erection, such as as a receptive partner?
What is the optimal next‑line systemic treatment for a patient with metastatic castration‑resistant prostate cancer adenocarcinoma with pleomorphic giant‑cell variant after recurrence following docetaxel therapy?
In a male patient with bone‑only metastatic castration‑resistant prostate cancer who has received docetaxel, continuous androgen deprivation therapy with orchiectomy, long‑term abiraterone, targeted radiation, a single dose of sipuleucel‑T (Provenge) discontinued due to allergy, and three cycles of Lu‑177‑PSMA‑617 (Pluvicto), and who started the investigational androgen‑receptor ligand‑directed degrader BMS‑986460 (1 mg daily) with an initial PSA rise followed by decline to 13.06 ng/mL and a recent 19 % increase to 15.6 ng/mL, castrate testosterone, stable hematologic parameters, and molecular findings of AR amplification, TP53 rearrangement, and CHEK2 alteration, is he still deriving clinical benefit from BMS‑986460 or is he developing emerging resistance?
Which American Society of Clinical Oncology (ASCO) 2026 finding best supports a move toward biology‑guided treatment intensification in metastatic hormone‑sensitive prostate cancer (mHSPC)?
What novel therapies are recommended for advanced prostate cancer based on molecular biomarkers such as homologous recombination repair gene alterations, PSMA positivity, and microsatellite instability‑high/mismatch repair deficiency?
In a patient with iron deficiency anemia who also has neutropenia (white blood cell count 2.57 ×10⁹/L) and normal platelets, what is the appropriate next step in evaluation and treatment?
What is the appropriate management of ventricular tachycardia (VT) and supraventricular tachycardia (SVT)?
Can a man with metastatic prostate cancer receiving androgen‑deprivation therapy and chemotherapy have sexual activity without a firm erection, such as as a receptive partner?
Which blood tests should be ordered for a woman entering menopause?
In an intubated patient receiving cyproheptadine for serotonin syndrome who is also on methadone, how should the serotonin syndrome be managed?
What is the pathophysiology of Myalgic Encephalomyelitis (ME)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.